For a 73-year-old woman on buprenorphine, oxycodone 5 mg as needed for pain, and currently prescribed lorazepam 1 mg as needed, trazodone 50 mg three tablets nightly, and mirtazapine 30 mg twice daily for sleep/mood, how should I manage her sleep medications on the initial visit if I do not want to continue these prescriptions?

Initial Visit Management of Sleep Medications in a 73-Year-Old on Buprenorphine

Do not provide refills for lorazepam at this first visit, and initiate a gradual taper plan for both trazodone and mirtazapine while addressing the underlying sleep disorder with evidence-based alternatives. This patient is on an alarmingly high and inappropriate polypharmacy regimen for sleep that poses significant risks for falls, cognitive impairment, and mortality in an elderly patient already on opioids 1, 2.

Immediate Safety Concerns

This 73-year-old woman is taking:

• Trazodone 150 mg nightly (three 50mg tablets) - far exceeding typical sleep doses
• Mirtazapine 60 mg nightly (two 30mg tablets) - double the FDA-approved starting dose and well above typical sleep doses 3
• Lorazepam 1 mg PRN - a benzodiazepine with high fall and cognitive impairment risk in elderly 1
• Buprenorphine + oxycodone - creating additional CNS depression risk

This combination creates compounded risks: The evidence clearly shows that benzodiazepines combined with opioids significantly increase overdose risk, and adding multiple sedating antidepressants amplifies CNS depression, fall risk, and cognitive impairment 1, 4.

Your First Visit Action Plan

1. Lorazepam - Do Not Refill

• Inform the patient you cannot continue benzodiazepines due to serious safety concerns in elderly patients, especially those on opioids 1, 4
• If she's been taking it regularly (not truly PRN): Provide only a 1-2 week bridge supply with a rapid taper schedule to prevent withdrawal
• If truly PRN/infrequent use: Discontinue immediately without taper
• Benzodiazepines are associated with falls, fractures, cognitive impairment, and increased mortality in elderly patients 1, 4

2. Trazodone 150 mg - Begin Taper

• Current dose is excessive; evidence shows 25-75 mg is more effective than higher doses for sleep 5
• Trazodone has moderate efficacy for sleep in older adults but lacks systematic evidence for chronic use 1, 2
• Taper schedule: Reduce by 25-50 mg every 1-2 weeks
  • Week 1-2: 100 mg nightly
  • Week 3-4: 50 mg nightly
  • Week 5-6: 25 mg nightly
  • Then reassess - may discontinue or maintain at 25 mg if beneficial 5

3. Mirtazapine 60 mg - Reduce Immediately

• This dose is inappropriate for sleep - FDA recommends starting at 15 mg for depression, and sleep studies show efficacy at 7.5-15 mg 3, 5
• At 60 mg, she's receiving an antidepressant dose with excessive sedation, weight gain risk, and no additional sleep benefit
• Reduction schedule:
  • Immediately reduce to 30 mg nightly (one tablet)
  • After 1-2 weeks: Reduce to 15 mg nightly
  • After another 1-2 weeks: Consider 7.5 mg (half tablet) or discontinue 3, 5
• The FDA label explicitly states dose changes should not occur more frequently than 1-2 weeks 3

Evidence-Based Sleep Management Going Forward

Prioritize Non-Pharmacological Treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment and should be initiated immediately 2, 6. This includes:

• Stimulus control therapy
• Sleep restriction therapy
• Relaxation techniques
• Sleep hygiene education (though not effective alone) 2, 1

If Pharmacotherapy Remains Necessary After Taper

The recommended sequence per guidelines 2:

1. First-line: Short-intermediate acting benzodiazepine receptor agonists (NOT benzodiazepines in elderly)

   • Zolpidem 5 mg (elderly dose)
   • Eszopiclone 1 mg (elderly dose)
   • Zaleplon 5 mg (elderly dose)
   • These have lower fall/cognitive risk than benzodiazepines 1

2. Alternative first-line: Ramelteon 8 mg (melatonin receptor agonist)

   • No abuse potential or motor/cognitive impairment 1
   • Particularly appropriate given her opioid use

3. Low-dose sedating antidepressant (if mood component exists):

   • Trazodone 25-50 mg (NOT 150 mg) 2, 5
   • Mirtazapine 7.5-15 mg (NOT 60 mg) 3, 5

Critical Communication Points

Tell the patient directly:

• "Your current sleep medication regimen is unsafe and not following medical guidelines, especially at your age and with your pain medications"
• "These high doses actually work against good sleep and increase your risk of falls, confusion, and serious drug interactions"
• "We need to carefully reduce these medications while I help you with better sleep strategies"
• "I cannot continue the lorazepam due to serious safety concerns with your other medications"

Document clearly:

• You are not "inheriting" this regimen but actively correcting unsafe prescribing
• Risks were explained to patient
• Taper plan provided in writing
• Patient educated about non-pharmacological sleep strategies
• Follow-up scheduled in 2 weeks to monitor taper and sleep 2

Special Considerations with Buprenorphine

• Buprenorphine itself can cause sleep disturbance 7
• The combination of buprenorphine with benzodiazepines significantly increases overdose and mortality risk 8
• Trazodone has been studied specifically in buprenorphine patients and shows efficacy at 50-150 mg, but your patient is already at the high end 7
• CNS depressant combinations with buprenorphine require extreme caution 9, 8

Common Pitfalls to Avoid

1. Don't continue these prescriptions "just for now" - each refill perpetuates harm
2. Don't taper too slowly - prolonged exposure to this polypharmacy is dangerous
3. Don't substitute one sedative for another - break the cycle with CBT-I
4. Don't ignore the anticholinergic burden - mirtazapine at high doses contributes to cognitive impairment 10
5. Don't assume the patient needs all these medications - often insomnia improves with deprescribing 4

Schedule close follow-up every 2 weeks during the taper period to monitor for withdrawal symptoms, rebound insomnia, and ensure patient safety 2, 4.